Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study

Nana Owusu-Boaitey[1,#], Timothy W. Russell[2], Gideon Meyerowitz-Katz[3], Andrew T. Levin[4,5,6], Daniel Herrera-Esposito[7,8,#,*]

Author affiliations:
1. Case Western Reserve University School of Medicine, Cleveland, USA
2. Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK
3. University of Wollongong, Wollongong, Australia
4. Dartmouth College, Hanover, USA
5. National Bureau for Economic Research, Cambridge, USA
6. Centre for Economic Policy Research, London, United Kingdom
7. University of Pennsylvania, Philadelphia, PA, USA
8. Universidad de la República, Uruguay

# These authors contributed equally to the work
* Corresponding author: dherresp@sas.upenn.edu

Abstract

We performed a systematic review and meta-analysis of SARS-CoV-2 serology studies to estimate time-dependent sensitivity for a large set of serological assays. We find that seroreversion depends strongly on the antigen and the analytic technique of the assay. We estimate the average time-varying sensitivity for different types of assays, as defined by their technical characteristics, which can be used to approximate the sensitivity of out-of-sample assays. We find large variability between types of assays, with assays of certain characteristics (nucleocapsid antigen, lateral flow assay) having an average of 20% sensitivity at 6 months, while others (receptor-binding domain antigen, sandwich design) have 98% sensitivity. Importantly, we estimate that almost a third of included assays depart significantly from manufacturer specified sensitivity after 6 months. Our analysis outlines the importance of monitoring the seroreversion of serological tests, and provides a tool for researchers to account for this phenomenon.

Introduction

Serological assays to measure antibodies against SARS-CoV-2 are an important tool for guiding the response to COVID-19, and for studying its epidemiology. These assays allow to estimate the proportion of individuals infected by SARS-CoV-2, which can be used to

determine the fatality rate of SARS-COV-2 (1–5); measure population-wide immunity (6,7); anticipate the effect of future infection waves (8,9); and estimate waning immunity with time (10). Throughout the pandemic, policymakers have been guided by the inferred number of past infections based on serological tests.

However, antibody levels wane with time after infection (11), causing serological assay sensitivity to change (12–14). We refer to the fall of assay sensitivity with time as seroreversion. Accounting for seroreversion when estimating previous infection numbers is important because of its potential to bias these estimates (1,15,16). Also, given the role of estimated infection numbers in driving public health policies such as vaccination programs and non-pharmaceutical interventions, understanding potential sources of bias in these estimates is important to COVID-19 policy making. More generally, understanding the limitations of serological testing is important to the management of other emerging infectious diseases where this tool is used. For example, in the ongoing monkeypox outbreak, estimates of prior exposure to the disease in Africa are based on serological studies with little assessment of the potential for seroreversion (17,18). Strikingly, a systematic evaluation of how seroreversion impacts the many approved serology assays for SARS-CoV-2 is still lacking, as well as general guidelines for researchers to correct for this phenomenon (17,18).

Although the time-varying sensitivity of serology assays has been evaluated in some previous studies, these are in general limited to either small numbers of assays, or short time spans (13,14,20–23). This limits the ability of these previous studies to properly quantify how different assay characteristics determine seroreversion, the variability of seroreversion across assays, and to provide general guidelines to account for seroreversion. Furthermore, variability between laboratories and batches of assays make it uncertain to what extent the results obtained by any such single study can be extrapolated to other serology studies. Other studies have analysed the variation across time of quantitative antibody levels or neutralisation capacity (11,13,24–28), but this does not provide a measure of time-varying sensitivity to correct for seroreversion in the serosurvey literature.

In this work we perform a systematic review and meta-analysis of serology studies of COVID-19, to better characterise seroreversion across existing assays. We collected time-specific sensitivity estimates from serological studies that tested individuals with a previous COVID-19 diagnosis, who had not received COVID-19 vaccines, and where the sample was not mainly composed of hospitalised patients (among other selection criteria aiming for samples more representative of the general population). After screening over 400 serological studies, we included 76 studies in our analysis, encompassing 50 different serological assays, 290 data points, and 44992 tests performed. The large dataset allowed

us to fit a hierarchical Bayesian model that simultaneously took into account the effects of different assay characteristics and potential sources of variability.

As a result, we estimated not only the time-varying sensitivity estimates for the assays included in the analysis, but also the average time-varying sensitivities for groups of assays of different characteristics. With these group-average sensitivities, the time-specific sensitivity of any SARS-CoV-2 seroassay with known characteristics can be approximated, providing the first general quantitative tool to correct for seroreversion across the COVID-19 literature. Our characterization of the differences between types of assays can also serve to reconcile seemingly conflicting results in the field, as well as to better design future serosurveys. Finally, we compare time-varying sensitivities to the sensitivities reported by assay manufacturers, thus providing the first overview of how seroreversion impacted the performance of emergency-approved seroassays in general.

Results

Assay variability in seroreversion

First, we fitted a model that did not consider assay characteristics. From this model, we obtained a slope and an intercept for each assay (**Figure 1**, see assay-specific curves in **Figure S1**). There is considerable variability in the estimated slopes and intercepts across assays. The random effect of the assay on the slope had a standard deviation of σ_{ua}=0.26 (95%CrI: 0.19; 0.36). Standard deviation for the intercepts random effect was σ_{ba}=0.66 (95%CrI: 0.31; 1.04). Most assays had decreasing sensitivity (negative slopes), although some assays had increasing sensitivities (shaded region **Figure 1**, **Figure S2**). We also found considerable variability between studies of a same assay, with a standard deviation of σ_{us}=0.81 (95%CrI: 0.67; 0.97).

We note that while some assays had multiple time points spanning several months, other assays only had a few time points (**Figure S1**). Thus, for assays with data covering short time periods, the quality of our models predictions will depend on the model's performance at extrapolation through time. We tested our model's performance at extrapolation using a cross-validation procedure specifically designed for this. We found that the predicted 95% credible intervals (CrI) contained the validation data 91.7% of the time (**Figure S1**). For assays with fewer than 9 data points (which comprise 99 of the 286 data points), 95.1% of the data points were within the cross validation CrI.

Figure 1. Assay slopes estimated without assay characteristics. Points show the mean of the posterior distribution of the slope for each assay, and horizontal bars show the 95% CrI. The slopes were obtained from the model that does not include effects of assay characteristics, but colour, point shape, and line type indicate the characteristics of the assays. The blue rectangle marks assays with slopes significantly greater than 0.

Assay characteristics determine seroreversion

Next, we wondered whether some of the variability in seroreversion across assays can be explained by assay characteristics. Based on previous studies (13,14) and preliminary analyses, we considered the effect of three assay characteristics: the antigen used, the analytic technology of the assay (lateral flow assay vs other techniques that require specialised laboratory equipment), and the detection design of the assay (sandwich vs indirect detection).

We fitted a new hierarchical model with terms for the different assay characteristics to influence the slope. We included a term for each of the three antigens, nucleocapsid, spike, and receptor-binding domain (RBD), fitting each assay with the slope corresponding to the 'best' antigen it targets. That is, if an assay targets both nucleocapsid and RBD, we used the RBD effect for this assay, assuming that sensitivity is limited by the most accurate antigen (the ordering was obtained from previous literature (13,14,29) and preliminary analyses). We also included a term for the use of lateral flow (LFA, rapid tests), and another term for the use of sandwich design. In summary, the slope of a given assay is determined by some combination of the antigen, LFA and sandwich effects.

Both the antigen targeted and the analytic technique used in the assay showed important effects (**Figure 2, Table 1**). LFA had an effect β_{LFA}=-0.31 (95%CrI: -0.47;-0.15), and β_{LFA}<0 in 100% of the posterior samples. The negative effect of LFA can be seen in the steeper slopes of the first column of **Figure 2** (LFA assays) compared to the second column (non-LFA assays). The sandwich design has a positive effect on the slope, with a mean value of β_{Sand}=0.29 (95%CrI: 0.16; 0.41), and with β_{Sand}>0 in 100% of the posterior samples. This positive effect on slope can be seen in the less steep drops in sensitivity of the third column of **Figure 2** (sandwich assays) compared to the second column (non-sandwich assays).

The antigen targeted had an important effect, with nucleocapsid showing faster seroreversion than spike protein, and with RBD showing the slowest seroreversion of the three. In particular, $\beta_{Nucleocapsid}$<β_{Spike} in 99.6% of the posterior samples, $\beta_{Nucleocapsid}$<β_{RBD} in 99.9% of the samples, and β_{Spike}<β_{RBD} in 94.7% of the samples. This effect can be seen in how the drops in sensitivity become smaller as we advance through the rows of **Figure 2**. All these results were robust to fitting each assay characteristic separately (**Figures S3, S4, S5**).

The full model had accuracy similar to the original model, with data points falling in the 95% CrI of their predictions 92.3% of the time for the full dataset, and 96.5% for the assays with fewer than 9 data points. However, the full model had more precise predictions, with narrower intervals than the basic model in 76% of the data points.

Figure 2. Sensitivity profiles for different assay characteristics. The sensitivity profile across time for each kind of assay is shown in a different panel. Rows indicate the targeted antigen (labelled on the left), and columns indicate the analytic technique (labelled on top). For example, the panel in the second row and second column shows assays that target the spike protein (second row label), and that do not use neither LFA nor sandwich design (second column label). The red lines show the mean sensitivity for each kind of assay. Shaded regions show the 95% CrI of the mean sensitivity of the group (i.e. not accounting for variability between assays). Black lines show the fits for individual assays. Grey dots show the data, with size proportional to the square root of sample size. Empty panels indicate that no assays with those characteristics were found for the analysis.

Table 1. Estimated sensitivities (in %) at each time after diagnosis, for each type of assay fitted in the analysis. Each row corresponds to a different type of test, with characteristics indicated in the first 3 columns. Parenthesis show the 95% CrI for each estimate. These estimates do not include the between-assay or between-study variability in their credible intervals. These sensitivities correspond to the red traces and shaded regions in **Figure 2**.

LFA	Sand-wich	Antigen	Month													
			1	2	3	4	5	6	7	8	9	10	11	12	13	14
Yes	No	Nucleo-capsid	83 (78-88)	73 (63-81)	59 (45-72)	44 (27-62)	31 (15-51)	20 (7-40)	13 (4-30)	8 (2-21)	5 (1-15)	3 (0-10)	2 (0-7)	1 (0-4)	1 (0-3)	0 (0-2)
Yes	No	Spike	86 (81-90)	80 (73-86)	73 (62-82)	64 (48-77)	54 (35-71)	44 (23-65)	35 (15-59)	27 (9-52)	20 (5-45)	15 (3-39)	11 (2-33)	8 (1-27)	6 (1-22)	4 (0-18)
Yes	No	RBD	87 (83-91)	83 (76-89)	79 (67-88)	73 (55-86)	67 (43-85)	60 (32-83)	53 (22-82)	47 (15-80)	41 (10-78)	35 (6-76)	30 (4-75)	26 (2-73)	22 (1-70)	19 (1-68)
No	No	Nucleo-capsid	87 (83-91)	83 (78-88)	78 (71-85)	73 (62-82)	66 (53-78)	59 (43-75)	52 (34-71)	44 (25-66)	37 (18-62)	31 (13-57)	25 (9-52)	21 (6-47)	17 (4-42)	13 (3-37)
No	No	Spike	89 (86-92)	88 (84-91)	87 (82-91)	86 (79-91)	84 (76-90)	83 (73-90)	81 (69-90)	79 (65-90)	77 (60-90)	75 (55-90)	73 (51-90)	71 (46-90)	69 (41-90)	67 (36-90)
No	No	RBD	90 (87-93)	90 (87-93)	90 (86-93)	90 (86-94)	90 (85-95)	90 (84-95)	90 (82-96)	90 (81-96)	90 (80-96)	90 (78-97)	90 (77-97)	90 (75-97)	90 (73-98)	90 (71-98)
No	Yes	Nucleo-capsid	90 (87-93)	90 (86-93)	90 (84-94)	89 (83-94)	89 (81-95)	89 (78-95)	88 (76-96)	88 (73-96)	88 (70-97)	87 (67-97)	87 (64-97)	86 (60-98)	86 (57-98)	85 (53-98)
No	Yes	RBD	93 (90-95)	94 (92-96)	96 (94-97)	97 (95-98)	98 (96-99)	98 (96-99)	99 (97-99)	99 (98-100)	99 (98-100)	99 (98-100)	100 (99-100)	100 (99-100)	100 (99-100)	100 (99-100)
Yes	Yes	Spike	89 (85-92)	88 (82-92)	86 (78-92)	85 (73-92)	83 (67-93)	81 (60-93)	79 (53-93)	76 (46-94)	74 (39-94)	71 (32-94)	69 (26-94)	66 (21-95)	64 (16-95)	61 (13-95)

We note that the value of the assay random effect of assay on the slope was σ_{ua}=0.11 (95%CrI: 0.06; 0.18), smaller than for the basic model, while the value of the random effect on the intercept of assay (σ_{ba}=0.69 (95%CrI: 0.30; 1.08)) and study (σ_{us}=0.81 (95%CrI: 0.67; 0.97)) were the same as in the original model.

Reliability of manufacturer reported sensitivities

Finally, we analysed how our estimates of time-varying sensitivity compare to assay specifications. For each assay, we searched for the sensitivity reported by the manufacturer. If this was not available, we searched for the sensitivity reported by the FDA, and if this was not found, we obtained it from other sources (e.g. the original publication). We found that 4 months after the original diagnosis, 22% of the assays have sensitivities below 75% of the original manufacturer sensitivities. By 6 months after diagnosis, 34% of the assays were below 75% of the manufacturer sensitivities, and 18% were below 50%. Thus, we find that some months after a COVID-19 wave, a considerable part of the serological assays included in this study are likely to underestimate previous infections.

Discussion

Serological testing has been widely used to understand COVID-19 dynamics and epidemiology, and to guide public health policy during the pandemic. But although it is common knowledge in the field that accounting for seroreversion is important, there is a lack of appropriate data and guidelines to correct for this phenomenon. This has led to very few studies correcting for seroreversion, and to seemingly conflicting reports in the literature regarding this phenomenon (1,15,16,19,30,31). Also, the high variability in seroreversion between assays, together with the lack of robust assay-specific estimates, make it uncertain how accurate existing adjustments for seroreversion are. In this work, we present the first large-scale systematic analysis of seroreversion across dozens of seroassays for SARS-CoV-2, making three major contributions to the field that can help fill the need for guidelines and information regarding seroreversion.

The first contribution is that we provide time-varying sensitivity estimates for 50 assays (**Table S1**), and estimates of the average time-varying sensitivity for different groups of assays as defined by their characteristics (**Table 1**, **Figure 2**). These average estimates can be used to approximate time-dependent sensitivity for any assay with known

characteristics for which there is no seroreversion data. Thus, we provide the first general tool to correct for seroreversion in an assay-specific manner across the SARS-CoV-2 literature. Furthermore, our model showed good performance at predicting assay sensitivity in a rigorous cross-validation analysis.

Our second contribution is the quantification of how seroreversion depends on assay characteristics, allowed by the considerably larger number of assays as compared to previous studies. We show that seroreversion depends on both the antigen targeted by the assay and on its analytical technology (**Figure 2**). Assays that use LFA technique (rapid tests) have faster seroreversions, while assays that use a sandwich (direct detection) design have slower seroreversions. Also, assays that use nucleocapsid tend to have faster decays than assays using spike protein, and even faster than those using RBD. These results can be important in guiding serosurvey design and assay selection in the future. For example, serosurveys looking to distinguish antibodies induced by vaccines and by infection will likely compare results from RBD targeting assays (which detect antibodies from both sources) against nucleocapsid targeting assays (which do not detect the antibodies generated by many of the available vaccines) (9,32). From our results, it follows that differences in seroreversion between these types of assays should be an important consideration in such studies.

Although this is in line with previous reports in the literature (13,14,20), previous analysis did not include all the same assay characteristics that we include, and did not quantify the effects of each characteristic in a simultaneous model fi. The striking differences between the different types of assays reported here outlines the need to do assay-specific corrections for seroreversion. For example, while we estimate the average sensitivity for RBD-targeting sandwich assays to be 98% (CrI95%: 96; 99) at 6 months after infection, we estimate average sensitivity of nucleocapsid-targeting LFA assays to be 20% (CrI95%: 7; 40) at the same time point. These differences may explain some of the more pessimistic estimates of the rate of seroreversion discussed in the literature (30) as being related to the use of LFA assays (33), or nucleocapsid-targeting assays (27) (although see Pérez-Olmeda et al., 2022 for strong seroreversion in an assay without these characteristics).

Our third contribution is a comparison between the sensitivities reported by manufacturers and regulatory organisms to the estimated time-changing sensitivities for a large set of assays. We estimate that a considerable fraction of the assays included in our analysis drop below 75% of their original reported sensitivity by 6 months after diagnosis. This underscores the potential of decaying seroassay sensitivity to bias epidemiological

parameter estimation, and possibly mislead public health response. This suggests that it is of interest to public health policy makers to ensure that in the future, assay manufacturers and regulatory organisms provide information and guidelines regarding seroreversion to researchers.

Our study has some limitations. Although we included more assays than previous studies, many of the included studies counted with data for only a few time points. Also, we were unable to test the effects of important parameters such as the age or the disease severity on seroreversion (13,14,27,34). Furthermore, as we analysed test data conditional on individuals having a previous COVID-19 diagnosis, it is likely that asymptomatic individuals are underrepresented in our sample. Finally, it is not clear how these results would extrapolate to vaccine-induced antibodies, or how these sensitivity estimates change for the different variants of the virus.

In conclusion, this study shows that accounting for seroreversion in serology-based estimates of past infections is important for understanding the COVID-19 pandemic, and that the usefulness of the continued use of serological testing to estimate present and past infection rates also depend on accounting for this factor. These conclusions generalise to other emerging and endemic diseases in which serology is used to characterise epidemiological characteristics and population exposure. We present a novel tool that will allow researchers to correct for seroreversion for most of the SARS-CoV-2 serology assays used in the literature.

Methods

Literature search

We performed a systematic literature review of seroprevalence studies to assess time-dependent sensitivity. The review included studies identified up to July 13, 2022 using search parameters detailed in a prior publication (31).

We supplemented this analysis with a search on Medrxiv, Biorxiv, PubMed, SSRN, and Google Scholar, on June 30, 2021 using the key "COVID-19 longitudinal, antibody waning" and on February 15, 2022 using the key "COVID-19 seroreversion". Additional studies were taken from a prior review (35). If a study cited prior publications assessing seroreversion in the same research cohort, we included those prior publications.

Inclusion and exclusion criteria for studies to be included in the analysis are listed in the **Supplementary methods**, but the results of the systematic search are summarised in **Figure 3**. A list of the included studies is shown in **Table 2**, and a more detailed list is presented in the GitHub repository associated with the project.

Figure 3. Prisma flow diagram. Flow diagram of the considered studies, showing excluded and included studies.

Statistical model

We fitted a hierarchical logistic regression Bayesian model to the data of sensitivity across time. We assume that the likelihood of the number of positive tests x out of N tested individuals (with previous COVID-19 diagnosis), is given by a binomial distribution with the sensitivity θ of that data point:

$$P(x|\theta) \propto \theta^x \; (1 - \theta)^{N-x} \qquad (1)$$

We assume that all data points are independent, conditional on their sensitivities. We model the sensitivity $\theta_{a,s,t}$ of assay a, at time t, in study s, with the logit function:

$$log\left(\frac{\theta_{a,s,t}}{1-\theta_{a,s,t}}\right) = \left(\mu + u_a + u_s\right) + \left(\beta + b_a\right) \times t \qquad (2)$$

where μ is the mean intercept, u_a and u_s are the effects on the intercept of assay and study,

respectively, β is the mean slope, and b_a is the effect of assay on the slope. We set flat priors

for μ and β. We set gamma priors with shape and rate parameters of 4 for σ_{ua}, σ_{us} and σ_{ba} .

For the model including effects of assay characteristics, we modify equation (2) to include effects of the antigen, of the use of LFA, and of the use of sandwich design in the following way:

$$log\left(\frac{\theta_{a,s,t}}{1-\theta_{a,s,t}}\right) = \left(\mu + u_a + u_s\right) + \left(\beta_{Nucleocapsid}N_a + \beta_{Spike}S_a + \beta_{RBD}RBD_a + \beta_{Sand}Snd + \beta_{LFA}LFA + b_a\right) \times t$$

In the equation above, $\beta_{Nucleocapsid}$, β_{Spike} and β_{RBD} are the slopes for assays targeting each kind of antigen that do not use neither LFA nor sandwich design. Parameters β_{Sand} and β_{LFA} are the effects of sandwich design and of LFA on the slope, respectively. Then, N_a, S_a, RBD_a, Snd_a and LFA_a are indicator variables that take values of either 0 or 1, and indicate what characteristics are associated to assay a.

We fitted the models using STAN (36), with 4 chains with 4000 draws each (1000 warmup) and default parameters.

Model cross-validation

We tested the models using cross-validation, grouping the validation data points so that validation involved extrapolation through time. First we selected an assay to be validated. Then, we separated the assay's data points into those with times earlier, and those with time later than the average time for the assay's data. We then obtained predictions for each of these two groups, using models fitted leaving out the respective data points. We repeated this procedure for all assays.

To obtain model predictions, we first sampled the sensitivity of a given data point from the fitted Bayesian model. Then, for each posterior draw of sensitivity, we drew 5 samples of the number of positive tests using the sampled sensitivity and Equation 1. This produced a posterior distribution of the number of positive tests for each data point. See further details of how the cross-validation was implemented in **Supplementary methods**.

Estimation of testing times

For data points with unknown times between COVID-19 diagnosis and antibody testing, we estimated these times using the case curves for the study location. First we looked for the cumulative number of reported cases by the date of the antibody testing study. Then, we identified the date, prior to antibody testing, at which half of that cumulative number of cases was attained, using case numbers from the COVID-19 DataHub [37], or data from official public health authorities. We used the delay between this date and the antibody testing as the estimated time of diagnosis to testing.

Table 2. Citations of the data sources for each of the assays included in the analysis.

Assay	Sources
Abbott Alinity	(38,39)
Abbott Alinity II Quant	(40)
Abbott Architect	(13–15,21,29,38,40–54)
AMP rapid test	(55)
Abingdon AbC-19	(20)
Beckman ACCESS	(56)
Biomerica rapid test	(20)
BioRad Platelia	(57)
Biozek rapid test	(20)
CCAHS	(58)
COVIDAR	(59–61)
Diasorin Liaison	(13,14,21,39,51–53,62)
EDI Novel Coronavirus	(12)
Elecsys anti-N	(12–15,21,38,39,52,62–71)
Elecsys anti-S	(14)
ERBALISA	(72,73)
Euroimmun anti-S	(12,14,15,29,39,41,51,53,74–82)
Euroimmun anti-N	(14,29)
Fortress Diagnostics	(83–85)

GenScript cPass	(14,29,40)
Hangzhou Clongene	(86)
IDK (Immundiagnostik)	(39)
InBios	(12)
Mehdi, in-house	(50)
THL Finland, in-house FMIA	(87)
THL Finland, in-house neutralisation assay	(87–89)
Gauteng, in-house Luminex	(90)
Tunis, in-house	(91)
Kavach ELISA IgG (Zydus)	(72)
Livzon lateral flow	(92,93)
LumiraDx	(20)
Luminex xMAP (RBD portion)	(94)
Massachusetts General Hospital	(95)
Mount Sinai (New York)	(96)
Roche rapid test	(20)
Orient Gene Biotech	(42)
SenASTrIS test	(97,98)
Siemens Advia Centaur	(52,99)
Siemens Advia anti-RBD	(49)
Standard Q	(100)
Sinai Health (Toronto)	(101)
Techno Genetics	(102)
Tosoh N sandwich	(70)
Tosoh N indirect	(70)
Tosoh S sandwich	(70)
Tosoh S indirect	(70)
University of Rio de Janeiro	(80,103)
Vitros Ortho (not total antibodies)	(13,104–107)

Vitros Ortho (total antibodies)	(13,14)
Wantai	(14,69,108,109)

Data and code availability

All the data and code needed to reproduce the analysis, the full pointers to the literature sources of the systematic review, and detailed comments about the review process are available at the associated GitHub page

https://github.com/dherrera1911/seroreversion_metaanalysis.

References

1. Brazeau NF, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling. Commun Med. 2022 May 19;2(1):1–13.

2. Herrera-Esposito D, de los Campos G. Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infect Dis. 2022 Mar 29;22(1):311.

3. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID‑19: An overview of systematic evaluations. Eur J Clin Invest [Internet]. 2021 May [cited 2021 Jul 25];51(5). Available from: https://onlinelibrary.wiley.com/doi/10.1111/eci.13554

4. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol. 2020 Dec 1;35(12):1123–38.

5. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature [Internet]. 2020 Nov 2 [cited 2020 Nov 5]; Available from: http://www.nature.com/articles/s41586-020-2918-0

6. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. JAMA. 2021 Oct 12;326(14):1400–9.

7. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med. 2022 Apr 7;386(14):1314–26.

8. Chapman LAC, Barnard RC, Russell TW, Abbott S, Zandvoort K van, Davies NG, et al. Unexposed populations and potential COVID-19 hospitalisations and deaths in European countries as per data up to 21 November 2021. Eurosurveillance. 2022 Jan 6;27(1):2101038.

9. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al. Adapting Serosurveys for the SARS-CoV-2 Vaccine Era. Open Forum Infect Dis. 2022 Feb 1;9(2):ofab632.

10. Lopman BA, Shioda K, Nguyen Q, Beckett SJ, Siegler AJ, Sullivan PS, et al. A framework for monitoring population immunity to SARS-CoV-2. Ann Epidemiol. 2021 Nov 1;63:75–8.

11. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 Mar;591(7851):639–44.

12. Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. Emerg Infect Dis. 2021 Mar;27(3):928–31.

13. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021 Jul 30;7(31):eabh3409.

14. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, et al. Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022 Jan 1;146:105052.

15. Lohse S, Sternjakob-Marthaler A, Lagemann P, Schöpe J, Rissland J, Seiwert N, et al. German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. Commun Med. 2022 May 18;2(1):1–12.

16. Shioda K, Lau MSY, Kraay ANM, Nelson KN, Siegler AJ, Sullivan PS, et al. Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies. Epidemiology. 2021 Jul;32(4):518–24.

17. MacNeil A, Abel J, Reynolds MG, Lash R, Fonnie R, Kanneh LD, et al. Serologic evidence of human orthopoxvirus infections in Sierra Leone. BMC Res Notes. 2011 Oct 28;4(1):465.

18. Reynolds MG, Lederman ER, Karem K, Mombouli JV, Moundeli O, Regnery R, et al. Prevalence of Antibodies against Orthopoxviruses among Residents of Likouala Region, Republic of Congo: Evidence for Monkeypox Virus Exposure. Am J Trop Med Hyg. 2007 Dec 1;77(6):1150–6.

19. Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, et al. The Serological

Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. mSphere. 2022 Jun 15;0(0):e00193-22.

20. McCance K, Wise H, Simpson J, Batchelor B, Hale H, McDonald L, et al. Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLOS ONE. 2022 Mar 31;17(3):e0266086.

21. Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, et al. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology (Phila). 2021 Oct 1;53(6):773–9.

22. Flower B, Brown JC, Simmons B, Moshe M, Frise R, Penn R, et al. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax. 2020 Dec;75(12):1082–8.

23. Perez-Saez J, Zaballa ME, Yerly S, Andrey DO, Meyer B, Eckerle I, et al. Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov 1;27(11):1695.e7-1695.e12.

24. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021 Jun 1;2(6):e240–9.

25. Di Germanio C, Simmons G, Kelly K, Martinelli R, Darst O, Azimpouran M, et al. SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion (Paris). 2021;61(9):2677–87.

26. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet. 2021 Mar 20;397(10279):1075–84.

27. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clin Infect Dis. 2021 Aug 1;73(3):e699–709.

28. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021 Feb 19;12(1):1162.

29. Garritsen A, Scholzen A, van den Nieuwenhof DWA, Smits APF, Datema ES, van Galen LS, et al. Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies. Infect Dis. 2021 Jul 3;53(7):498–512.

30. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling elderly populations. Eur J Epidemiol. 2022 Mar;37(3):235–49.

31. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022 May 1;7(5):e008477.

32. Stringhini S, Zaballa ME, Pullen N, Perez-Saez J, Mestral C de, Loizeau AJ, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance. 2021 Oct 28;26(43):2100830.

33. Herrington DM, Sanders JW, Wierzba TF, Alexander-Miller M, Espeland M, Bertoni AG, et al. Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. BMC Infect Dis. 2021 Aug 30;21(1):889.

34. Pérez-Olmeda M, Saugar JM, Fernández-García A, Pérez-Gómez B, Pollán M, Avellón A, et al. Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain. J Clin Virol. 2022 Apr 1;149:105130.

35. Fei Y, Xu H, Zhang X, Musa SS, Zhao S, He D. Seroprevalence and infection attack rate of COVID-19 in Indian cities. Infect Dis Model [Internet]. 2022 Mar 10 [cited 2022 Mar 16]; Available from: https://www.sciencedirect.com/science/article/pii/S2468042722000094

36. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A Probabilistic Programming Language. J Stat Softw. 2017 Jan 11;76(1):1–32.

37. Guidotti E, Ardia D. COVID-19 Data Hub. J Open Source Softw. 2020 Jul 10;5(51):2376.

38. Mallon PWG, Tinago W, Leon AG, McCann K, Kenny G, McGettrick P, et al. Dynamic Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses. Open Forum Infect Dis. 2021 Aug 1;8(8):ofab122.

39. Eberhardt KA, Dewald F, Heger E, Gieselmann L, Vanshylla K, Wirtz M, et al. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms. 2021 Apr;9(4):733.

40. McGregor R, Craigie A, Jack S, Upton A, Moreland NJ, Ussher J. The Persistence of Neutralising Antibodies up to 11 months after SARS-CoV-2 Infection in the Southern Region of New Zealand [Internet]. medRxiv; 2021 [cited 2022 Sep 7]. p. 2021.10.26.21265501. Available from: https://www.medrxiv.org/content/10.1101/2021.10.26.21265501v1

41. Knabl L, Mitra T, Kimpel J, Rössler A, Volland A, Walser A, et al. High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. Commun Med. 2021 Jun 30;1(1):1–9.

42. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et

al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020 Aug 22;396(10250):535–44.

43. Samore MH, Looney A, Orleans B, Greene T, Seegert N, Delgado JC, et al. Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA. Emerg Infect Dis. 2021 Nov;27(11):2786–94.

44. Tadesse EB, Endris AA, Solomon H, Alayu M, Kebede A, Eshetu K, et al. Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020. Int J Infect Dis. 2021 Oct 1;111:179–85.

45. Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021 Mar 1;9(3):e257–66.

46. Ayub T, Raja MW, Khan SMS, Haq I, Qureshi MA, Majid S, et al. Seroprevalence of SARS CoV 2 specific Ig G antibodies in District Srinagar, Kashmir: a population based study. Int J Community Med Public Health. 2021 Mar 25;8(4):1792.

47. Khan SMS, Qurieshi MA, Haq I, Majid S, Ahmad J, Ayub T, et al. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020. BMJ Open. 2021 Sep 1;11(9):e053791.

48. Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study. PLOS Med. 2021 Dec 10;18(12):e1003877.

49. Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021. Int J Infect Dis. 2021 Jul 1;108:145–55.

50. Thiruvengadam R, Chattopadhyay S, Mehdi F, Desiraju BK, Chaudhuri S, Singh S, et al. Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study. Am J Trop Med Hyg. 2021 Jul 7;105(1):66–72.

51. Tea F, Stella AO, Aggarwal A, Darley DR, Pilli D, Vitale D, et al. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLOS Med. 2021 Jul 6;18(7):e1003656.

52. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis. 2021 Feb 1;223(3):389–98.

53. Kahre E, Galow L, Unrath M, Haag L, Blankenburg J, Dalpke AH, et al. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays. Sci Rep. 2021 Jul 21;11(1):14893.

54. Kumar MS, Thangaraj JWV, Saravanakumar V, Selvaraju S, Kumar CPG, Sabarinathan R, et al. Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020. Trans R Soc Trop Med Hyg. 2021 Nov 1;115(11):1350–2.

55. Šmigelskas K, Petrikonis K, Kasiulevičius V, Kalėdienė R, Jakaitienė A, Kaselienė S, et al. SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey. Acta Medica Litu. 2021;28(1):48–58.

56. Kennedy JL, Forrest JC, Young SG, Amick B, Williams M, James L, et al. Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas. Open Forum Infect Dis. 2022 May 1;9(5):ofac154.

57. Sullivan PS, Siegler AJ, Shioda K, Hall EW, Bradley H, Sanchez T, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020–December 2020. Clin Infect Dis. 2022 Apr 1;74(7):1141–50.

58. Bushnik T. COVID-19 infection in the Canadian household population. Health Rep. 2022;33(82):12.

59. Schonfeld D, Fernández H, Ramírez J, Acosta D, Becerra J, Wettstein M, et al. SARS-CoV-2 seroprevalence in the city of Puerto Madryn: Underdiagnosis and relevance of children in the pandemic. PLOS ONE. 2022 Mar 14;17(3):e0263679.

60. Ojeda DS, Ledesma MMGL, Pallarés HM, Navarro GSC, Sanchez L, Perazzi B, et al. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLOS Pathog. 2021 Jan 14;17(1):e1009161.

61. Longueira Y, Polo ML, Group I working, Turk G, Laufer N, Group B de EICC working. Dynamics of SARS-CoV-2-specific antibodies during and after COVID19: Lessons from a biobank in Argentina [Internet]. medRxiv; 2021 [cited 2022 Sep 7]. p. 2021.01.31.21250167. Available from: https://www.medrxiv.org/content/10.1101/2021.01.31.21250167v1

62. Dorigatti I, Lavezzo E, Manuto L, Ciavarella C, Pacenti M, Boldrin C, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'. Nat Commun. 2021 Jul 19;12(1):4383.

63. Kar SS, Sarkar S, Murali S, Dhodapkar R, Joseph NM, Aggarwal R. Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020. Emerg Infect Dis. 2021 Feb;27(2):666–9.

64. Herlinda O, Bella A, Kusnadi G, Nurshadrina DS, Akbar MT, Nida S, et al. Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in

Jakarta, Indonesia. PLOS ONE. 2021 Dec 23;16(12):e0261931.

65. Laxmaiah A, Rao NM, Arlappa N, Babu J, Kumar PU, Singh P, et al. SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021. IJID Reg. 2022 Mar 1;2:1–7.

66. https://www.mhlw.go.jp/content/10900000/000934787.pdf [Internet]. https://www.mhlw.go.jp/content/10900000/000934787.pdf. [cited 2022 Sep 7]. Available from: https://www.mhlw.go.jp/content/10900000/000934787.pdf

67. Kshatri JS, Bhattacharya D, Kanungo S, Giri S, Palo SK, Parai D, et al. Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India. Sci Rep. 2021 May 18;11(1):10551.

68. Kshatri JS, Bhattacharya D, Praharaj I, Mansingh A, Parai D, Kanungo S, et al. Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys. Epidemiol Infect [Internet]. 2021 ed [cited 2022 Apr 8];149. Available from: https://www.cambridge.org/core/journals/epidemiology-and-infection/article/seroprevalen ce-of-sarscov2-in-bhubaneswar-india-findings-from-three-rounds-of-community-surveys/ 29A7905F297A1EFA68749AC3C6383300

69. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020 Oct 29;383(18):1724–34.

70. Goto A, Go H, Miyakawa K, Yamaoka Y, Ohtake N, Kubo S, et al. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors. Front Microbiol [Internet]. 2021 [cited 2022 Sep 7];12. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2021.661187

71. Alkharaan H, Bayati S, Hellström C, Aleman S, Olsson A, Lindahl K, et al. Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. J Infect Dis. 2021 Aug 2;224(3):407–14.

72. Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study. Trans R Soc Trop Med Hyg. 2022 Mar 2;116(3):242–51.

73. Satpati PS, Sarangi SS, Gantait KS, Endow S, Mandal NC, Panchanan K, et al. Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India [Internet]. medRxiv; 2020 [cited 2022 Apr 8]. p. 2020.09.12.20193219. Available from: https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1

74. Warszawski J, Beaumont AL, Seng R, de Lamballerie X, Rahib D, Lydié N, et al.

Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort. BMC Infect Dis. 2022 Jan 9;22(1):41.

75. Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol. 2021 Oct 1;50(5):1458–72.

76. Santos-Hövener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Eurosurveillance. 2020 Nov 26;25(47):2001752.

77. Ghose A, Bhattacharya S, Karthikeyan AS, Kudale A, Monteiro JM, Joshi A, et al. Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in an Indian metropolitan city [Internet]. medRxiv; 2020 [cited 2022 Sep 7]. p. 2020.11.17.20228155. Available from: https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2

78. Gornyk D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Bojara G, et al. SARS-CoV-2 Seroprevalence in Germany - A Population Based Sequential Study in Five Regions [Internet]. Rochester, NY: Social Science Research Network; 2021 Apr [cited 2021 Dec 4]. Report No.: ID 3834300. Available from: https://papers.ssrn.com/abstract=3834300

79. RKI - CORONA-MONITORING lokal - Corona-Monitoring lokal [Internet]. [cited 2022 Sep 7]. Available from: https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Str aubing.html

80. Alvim RGF, Lima TM, Rodrigues DAS, Marsili FF, Bozza VBT, Higa LM, et al. Development and large-scale validation of a highly accurate SARS-COV-2 serological test using regular test strips for autonomous and affordable finger-prick sample collection, transportation, and storage [Internet]. medRxiv; 2021 [cited 2022 Sep 7]. p. 2020.07.13.20152884. Available from: https://www.medrxiv.org/content/10.1101/2020.07.13.20152884v6

81. Vanshylla K, Cristanziano VD, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 [Internet]. bioRxiv; 2021 [cited 2022 Sep 7]. p. 2021.01.26.428207. Available from: https://www.biorxiv.org/content/10.1101/2021.01.26.428207v1

82. Parrott JC, Maleki AN, Vassor VE, Osahan S, Hsin Y, Sanderson M, et al. Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based Survey. J Infect Dis. 2021 Jul 15;224(2):188–95.

83. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat Commun. 2021 Feb 10;12(1):905.

84. Ward H, Cooke GS, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Reg Health – Eur [Internet]. 2021 May 1 [cited 2022 Apr 8];4. Available from: https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00075-2/fulltext

85. Ward H, Atchison C, Whitaker M, Donnelly CA, Riley S, Ashby D, et al. Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults [Internet]. 2021 Jul [cited 2021 Dec 3] p. 2021.07.21.21260926. Available from: https://www.medrxiv.org/content/10.1101/2021.07.21.21260926v1

86. Iruzubieta P, Fernández-Lanas T, Rasines L, Cayon L, Álvarez-Cancelo A, Santos-Laso A, et al. Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Sci Rep. 2021 May 10;11(1):9819.

87. Haveri A, Ekström N, Solastie A, Virta C, Österlund P, Isosaari E, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51(12):3202–13.

88. Study by THL and Welfare and the City of Helsinki: Antibodies elicited by coronavirus infection persist for at least four months - Press release - THL [Internet]. Finnish Institute for Health and Welfare (THL), Finland. [cited 2022 Sep 7]. Available from: https://thl.fi/en/web/thlfi-en/-/study-by-thl-and-welfare-and-the-city-of-helsinki-antibodies-elicited-by-coronavirus-infection-persist-for-at-least-four-months

89. THL's study: Majority of people who have had a coronavirus infection retain antibodies for over six months - Press release - THL [Internet]. Finnish Institute for Health and Welfare (THL), Finland. [cited 2022 Sep 7]. Available from: https://thl.fi/en/web/thlfi-en/-/thl-s-study-majority-of-people-who-have-had-a-coronavirus-infection-retain-antibodies-for-over-six-months

90. Mutevedzi PC, Kawonga M, Kwatra G, Moultrie A, Baillie V, Mabena N, et al. Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. Int J Epidemiol. 2022 Apr 1;51(2):404–17.

91. Cherif I, Kharroubi G, Chaabane S, Yazidi R, Dellagi M, Snoussi MA, et al. COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the general population of the capital city Tunis [Internet]. In Review; 2022 Feb [cited 2022 Sep 7]. Available from: https://www.researchsquare.com/article/rs-1317280/v2

92. Royo-Cebrecos C, Vilanova D, López J, Arroyo V, Pons M, Francisco G, et al. Mass

SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. Lancet Reg Health - Eur. 2021 Jun 1;5:100119.

93. Fogh K, Strange JE. Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19. Microbiol Spectr. 9(3):12.

94. Sood N, Pernet O, Lam CN, Klipp A, Kotha R, Kovacs A, et al. Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study. JAMA Netw Open. 2022 Jan 20;5(1):e2144258.

95. Matias WR, Fulcher IR, Sauer SM, Nolan CP, Guillaume Y, Zhu J, et al. Disparities in SARS-CoV-2 exposure: evidence from a citywide seroprevalence study in Holyoke, Massachusetts, USA [Internet]. medRxiv; 2021 [cited 2022 Sep 7]. p. 2021.10.13.21264975. Available from: https://www.medrxiv.org/content/10.1101/2021.10.13.21264975v1

96. Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, et al. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021. Emerg Infect Dis. 2022 Mar;28(3):556–63.

97. Blankenberger J, Kaufmann M, Albanese E, Amati R, Anker D, Camerini AL, et al. Is living in a household with children associated with SARS-CoV-2 seropositivity in adults? Results from the Swiss national seroprevalence study Corona Immunitas. BMC Med. 2022 Jun 20;20(1):233.

98. Dupraz J, Butty A, Duperrex O, Estoppey S, Faivre V, Thabard J, et al. Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. Open Forum Infect Dis. 2021 Jul 1;8(7):ofab149.

99. Castro LC e, Pereira AHG, Ribeiro R, Alves C, Veloso L, Vicente V, et al. Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal. Emerg Infect Dis [Internet]. 2021 Nov [cited 2022 Sep 7];27(11). Available from: https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article

100. Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, Martel KS, Valle A, Valverde J, et al. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. eClinicalMedicine [Internet]. 2021 Apr 1 [cited 2022 Sep 7];34. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext

101. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. 2020 Oct 8;5(52):eabe5511.

102. Hoballah A, El Haidari R, Siblany G, Abdel Sater F, Mansour S, Hassan H, et al.

SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey. BMC Infect Dis. 2022 Jan 10;22(1):42.

103. Silveira MF, Mesenburg M, Dellagostin OA, Oliveira NR, Maia MAC, Santos FDS, et al. Time-Dependent Decay of Detectable Antibodies Against SARS-CoV-2: A Comparison of ELISA with Two Batches of a Lateral-Flow Test [Internet]. Rochester, NY: Social Science Research Network; 2021 Jan [cited 2021 Jul 26]. Report No.: ID 3757411. Available from: https://papers.ssrn.com/abstract=3757411

104. Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. Am J Med. 2021 Apr 1;134(4):526-534.e11.

105. Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second Wave of the COVID-19 Pandemic in Delhi, India: High Seroprevalence Not a Deterrent? Cureus [Internet]. 2021 Oct 24 [cited 2022 Sep 7];13(10). Available from: https://www.cureus.com/articles/72911-second-wave-of-the-covid-19-pandemic-in-delhi-india-high-seroprevalence-not-a-deterrent

106. Sharma P, Basu S, Mishra S, Gupta E, Aggarwal R, Kale P, et al. SARS-CoV-2 seroprevalence in Delhi, India - September-October 2021 – a population based seroepidemiological study [Internet]. medRxiv; 2021 [cited 2022 Sep 7]. p. 2021.12.28.21268451. Available from: https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1

107. Abdul-Raheem R, Moosa S, Waheed F, Aboobakuru M, Ahmed IN, Rafeeg FN, et al. A sero-epidemiological study after two waves of the COVID-19 epidemic. Asian Pac J Allergy Immunol. 2021 Dec 26;

108. Cito F, Amato L, Di Giuseppe A, Danzetta ML, Iannetti S, Petrini A, et al. A COVID-19 Hotspot Area: Activities and Epidemiological Findings. Microorganisms. 2020 Nov;8(11):1711.

109. Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. Eur J Epidemiol [Internet]. 2021 Aug 22 [cited 2021 Aug 26]; Available from: https://doi.org/10.1007/s10654-021-00796-8